TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy

Chimeric antigen receptor T (CAR T) cell immunotherapy has shown remarkable efficacy in non-Hodgkin’s lymphoma (NHL) patients. Minimal residual disease (MRD) monitoring in NHL is essential after CAR T cell therapy, which can be achieved by monitoring circulating tumor DNA (ctDNA). The mutation of TP...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liting, Mu, Wei, Gu, Jia, Xiao, Min, Huang, Liang, Zheng, Miao, Li, Chunrui, Xiao, Yi, Zhou, Jianfeng, Long, Xiaolu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151854/
https://www.ncbi.nlm.nih.gov/pubmed/34066756
http://dx.doi.org/10.3390/diagnostics11050844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151854/
https://www.ncbi.nlm.nih.gov/pubmed/34066756
http://dx.doi.org/10.3390/diagnostics11050844

Ejemplares similares